These activated DCs promoted significant tumor extinction or no tumor formation in the prophylactic assay [165], but they failed to retard tumor growth in the therapeutic regimen, which was partially recovered in combination with IL-2 exogenous administration [166]. The gene discussed is IL2; the disease is neoplasm.